Clinical impact of subcutaneous treprostinil in trisomy 21 patient with pulmonary arterial hypertension associated with CHD

Clinical impact of subcutaneous treprostinil in trisomy 21 patient with pulmonary arterial hypertension associated with CHD

Subcutaneous treprostinil is commonly used to improve idiopathic pulmonary arterial hypertension in children. However, its effectiveness has not been reported in trisomy 21. We report the case of 9-year-old boy in trisomy 21 with CHD-pulmonary artery hypertension after surgical correction of CHD. Ha...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiology in the young 2022-09, Vol.32 (9), p.1502-1504
Hauptverfasser: Numata, Ryusuke, Takigiku, Kiyohiro, Takei, Kouta
Format: Artikel
Sprache:eng
Schlagworte:
Airway management
Cardiac catheterization
Catheters
Down syndrome
General Cardiology
Hemodynamics
Hypertension
Intellectual disabilities
Patients
Pediatrics
Pulmonary arteries
Pulmonary artery
Pulmonary hypertension
Surgery
Trisomy
Veins & arteries
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Subcutaneous treprostinil is commonly used to improve idiopathic pulmonary arterial hypertension in children. However, its effectiveness has not been reported in trisomy 21. We report the case of 9-year-old boy in trisomy 21 with CHD-pulmonary artery hypertension after surgical correction of CHD. Haemodynamics and exercise capacity dramatically improved with a transition from oral selexipag to subcutaneous treprostinil.
ISSN:1047-9511
1467-1107
DOI:10.1017/S1047951121005096